Our data suggest that a mechanism exists whereby glucose supplementation early in the evolution of the systemic inflammatory response syndrome combines to drive the development of peripheral insulin resistance and suppresses pancreatic insulin production thereby amplifying metabolic decompensation and worsening the degree of hyperglycemia and potentially outcome. This evidence concerns the gene INS and Insulin resistance.